Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palvella Therapeutics ( (PVLA) ) has shared an update.
On September 24, 2025, Palvella Therapeutics announced the expansion of its QTORIN™ 3.9% rapamycin anhydrous gel development program to include clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FDA-approved therapies. The company plans to initiate a Phase 2 trial in the second half of 2026, aiming to address the unmet medical needs of over 50,000 diagnosed patients in the U.S. This strategic move aligns with Palvella’s focus on introducing the first FDA-approved therapies for rare skin diseases, potentially enhancing its industry positioning and offering new hope for stakeholders affected by these conditions.
The most recent analyst rating on (PVLA) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases that currently lack FDA-approved treatments. The company is advancing a broad pipeline of product candidates based on its patented QTORIN™ platform, with its lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, under evaluation in clinical trials for various skin conditions.
Average Trading Volume: 164,713
Technical Sentiment Signal: Hold
Current Market Cap: $651.1M
For an in-depth examination of PVLA stock, go to TipRanks’ Overview page.